NCT03532139 is a Phase 2 clinical trial of Enoxaparin in Ovarian Cancer, sponsored by Beth Israel Deaconess Medical Center.

Who is sponsoring NCT03532139?

NCT03532139 is sponsored by Beth Israel Deaconess Medical Center.

What drugs are being tested in NCT03532139?

Interventions in NCT03532139: Enoxaparin, Enoxaparin + Rosuvastatin, Thromboprophylaxis.

What condition does NCT03532139 study?

NCT03532139 studies Ovarian Cancer.

Is NCT03532139 still recruiting?

NCT03532139 is currently completed. Last updated 23 January 2025.

Last reviewed 2025-01-23 · How we verify

NCT03532139

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)

Completed Phase 2 Last updated 23 January 2025

What this trial tests

Phase 2 trial testing Enoxaparin in Ovarian Cancer in 24 participants. Completed in 31 May 2024.

Timeline

25 July 2018

Primary endpoint
31 December 2023

31 May 2024

Quick facts

Lead sponsor	Beth Israel Deaconess Medical Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	24
Start date	25 July 2018
Primary completion	31 December 2023
Estimated completion	31 May 2024
Sites	2 locations across United States

Drugs / interventions tested

Enoxaparin — full drug profile →
Enoxaparin + Rosuvastatin — full drug profile →
Thromboprophylaxis — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Beth Israel Deaconess Medical Center

Who can join

18 and older, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is studying a combination of two drug interventions called rosuvastatin and enoxaparin as a possible preventative measure against developing venous blood clots (such deep vein thrombosis or pulmonary embolism). . The drugs involved in this study are: * Rosuvastatin, also known as Crestor * Enoxaparin

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Inflammation and tumor progression: signaling pathways and targeted intervention.
Zhao H, Wu L, Yan G, Chen Y, et al · · 2021 · cited 1932× · PMID 34248142 · DOI 10.1038/s41392-021-00658-5
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
Singh RR, O'Reilly EM. · · 2020 · cited 119× · PMID 32306207 · DOI 10.1007/s40265-020-01304-0
Mutant p53, the Mevalonate Pathway and the Tumor Microenvironment Regulate Tumor Response to Statin Therapy.
Pereira M, Matuszewska K, Glogova A, Petrik J. · · 2022 · cited 17× · PMID 35884561 · DOI 10.3390/cancers14143500
Genetic and therapeutic heterogeneity shape the baseline and longitudinal immune ecosystem of ovarian clear cell carcinoma.
Xia S, Chen L, Yu M, Li J, et al · · 2024 · cited 13× · PMID 39608974 · DOI 10.1136/jitc-2024-010069
Dysregulation of Cholesterol Homeostasis in Ovarian Cancer.
Qusairy Z, Gangloff A, Leung SOA. · · 2023 · cited 9× · PMID 37754524 · DOI 10.3390/curroncol30090609
Statins for the primary prevention of venous thromboembolism.
Wang Z, Zhang P, Tian J, Zhang P, et al · · 2024 · cited 4× · PMID 39498835 · DOI 10.1002/14651858.cd014769.pub2
The efficacy of rosuvastatin to reduce circulating tissue factor extracellular vesicles after ovarian cancer surgery.
Osataphan S, Patell R, Babuta M, Rosovsky RP, et al · · 2025 · PMID 40472284 · DOI 10.1182/bloodadvances.2025016107

Verify or expand the search:

Other trials of Enoxaparin

Trials testing the same drug.

NCT07462182 — Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction · NA · not yet recruiting
NCT07312851 — A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Parti · Phase 1 · recruiting
NCT07015905 — REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults · Phase 3 · recruiting
NCT06818279 — Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis · Phase 2, PHASE3 · not yet recruiting
NCT06689241 — Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery · NA · recruiting

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Beth Israel Deaconess Medical Center trials

Trials by the same sponsor.

NCT07352657 — Remote Alert Pathway To Optimize CaRe of Cardiac Implantable Electrical Devices: The RAPTOR-CIED Study (Main Phase) · NA · not yet recruiting
NCT07531602 — Effect of PEEP on Cardiac Function · NA · not yet recruiting
NCT07534683 — Primed to Thrive: Investigating the Combined Impact of Mindfulness Education and Meditation Practice on Psychological an · NA · not yet recruiting
NCT07277244 — Low-Intensity Mechanical Ventilation in the Operating Room: a Pilot Study · NA · enrolling by invitation
NCT06896474 — SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03532139 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beth Israel Deaconess Medical Center
Last refreshed: 23 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03532139.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing